Salvage surgery for locoregional failure after definitive radiotherapy for base of tongue cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this study, the results of definitive radiotherapy (RT) and salvage surgery treatment of base of tongue cancer were evaluated. A total of 94 consecutive patients (16 female and 78 male) with T1-4, N0-3 and M0 disease underwent definitive RT between 1992 and 2005. External beam RT alone (mean dose, 63 Gy) or external beam RT (mean dose 61 Gy) with brachytherapy boost (mean dose, 17 Gy) was given for 50 and 44 patients, respectively. Eight patients were subjected to neck node dissection, generally at the time of brachytherapy. At a median follow-up time of 95 months, 37 (39%) patients had no residual disease or locoregional recurrence, 34 (36%) patients had locoregional residual disease and 23 (25%) patients developed locoregional recurrence. The 5-year cause-specific survival for all patients was 45% (43 of 94). In multivariate analysis, N2-3 stage and histological grade 3 proved to be independent negative predictors of cause-specific survival (relative risk: 22 and 3.1, respectively). The overall number of patients with locoregional failure was 57. Salvage surgery was possible in 18 (32%) patients; more than half of the patients (31 of 57) with locoregional failure were not suitable for salvage surgery due to unresectable disease, poor health status or distant metastasis. Salvage surgery was successful in 10 (56%) patients, while 8 patients developed a second locoregional recurrence. For patients undergoing definitive RT, more effective follow-up and care is needed to increase the rate of salvage surgery.

Original languageEnglish
Pages (from-to)803-806
Number of pages4
JournalIn Vivo
Volume22
Issue number6
Publication statusPublished - Nov 2008

Fingerprint

Tongue Neoplasms
Salvaging
Radiotherapy
Surgery
Dosimetry
Dissection
Brachytherapy
Recurrence
Health
Salvage Therapy
Aftercare
Neck Dissection
Survival
Health Status

Keywords

  • Base of tongue cancer
  • Radiotherapy
  • Salvage surgery

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Salvage surgery for locoregional failure after definitive radiotherapy for base of tongue cancer. / Kásler, M.; Fodor, J.; Oberna, Ferenc; Major, T.; Polgár, C.; Takácsi, Nagy Z.

In: In Vivo, Vol. 22, No. 6, 11.2008, p. 803-806.

Research output: Contribution to journalArticle

@article{d4b1cc19db5f45128c77f47fe888cc65,
title = "Salvage surgery for locoregional failure after definitive radiotherapy for base of tongue cancer",
abstract = "In this study, the results of definitive radiotherapy (RT) and salvage surgery treatment of base of tongue cancer were evaluated. A total of 94 consecutive patients (16 female and 78 male) with T1-4, N0-3 and M0 disease underwent definitive RT between 1992 and 2005. External beam RT alone (mean dose, 63 Gy) or external beam RT (mean dose 61 Gy) with brachytherapy boost (mean dose, 17 Gy) was given for 50 and 44 patients, respectively. Eight patients were subjected to neck node dissection, generally at the time of brachytherapy. At a median follow-up time of 95 months, 37 (39{\%}) patients had no residual disease or locoregional recurrence, 34 (36{\%}) patients had locoregional residual disease and 23 (25{\%}) patients developed locoregional recurrence. The 5-year cause-specific survival for all patients was 45{\%} (43 of 94). In multivariate analysis, N2-3 stage and histological grade 3 proved to be independent negative predictors of cause-specific survival (relative risk: 22 and 3.1, respectively). The overall number of patients with locoregional failure was 57. Salvage surgery was possible in 18 (32{\%}) patients; more than half of the patients (31 of 57) with locoregional failure were not suitable for salvage surgery due to unresectable disease, poor health status or distant metastasis. Salvage surgery was successful in 10 (56{\%}) patients, while 8 patients developed a second locoregional recurrence. For patients undergoing definitive RT, more effective follow-up and care is needed to increase the rate of salvage surgery.",
keywords = "Base of tongue cancer, Radiotherapy, Salvage surgery",
author = "M. K{\'a}sler and J. Fodor and Ferenc Oberna and T. Major and C. Polg{\'a}r and Tak{\'a}csi, {Nagy Z.}",
year = "2008",
month = "11",
language = "English",
volume = "22",
pages = "803--806",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Salvage surgery for locoregional failure after definitive radiotherapy for base of tongue cancer

AU - Kásler, M.

AU - Fodor, J.

AU - Oberna, Ferenc

AU - Major, T.

AU - Polgár, C.

AU - Takácsi, Nagy Z.

PY - 2008/11

Y1 - 2008/11

N2 - In this study, the results of definitive radiotherapy (RT) and salvage surgery treatment of base of tongue cancer were evaluated. A total of 94 consecutive patients (16 female and 78 male) with T1-4, N0-3 and M0 disease underwent definitive RT between 1992 and 2005. External beam RT alone (mean dose, 63 Gy) or external beam RT (mean dose 61 Gy) with brachytherapy boost (mean dose, 17 Gy) was given for 50 and 44 patients, respectively. Eight patients were subjected to neck node dissection, generally at the time of brachytherapy. At a median follow-up time of 95 months, 37 (39%) patients had no residual disease or locoregional recurrence, 34 (36%) patients had locoregional residual disease and 23 (25%) patients developed locoregional recurrence. The 5-year cause-specific survival for all patients was 45% (43 of 94). In multivariate analysis, N2-3 stage and histological grade 3 proved to be independent negative predictors of cause-specific survival (relative risk: 22 and 3.1, respectively). The overall number of patients with locoregional failure was 57. Salvage surgery was possible in 18 (32%) patients; more than half of the patients (31 of 57) with locoregional failure were not suitable for salvage surgery due to unresectable disease, poor health status or distant metastasis. Salvage surgery was successful in 10 (56%) patients, while 8 patients developed a second locoregional recurrence. For patients undergoing definitive RT, more effective follow-up and care is needed to increase the rate of salvage surgery.

AB - In this study, the results of definitive radiotherapy (RT) and salvage surgery treatment of base of tongue cancer were evaluated. A total of 94 consecutive patients (16 female and 78 male) with T1-4, N0-3 and M0 disease underwent definitive RT between 1992 and 2005. External beam RT alone (mean dose, 63 Gy) or external beam RT (mean dose 61 Gy) with brachytherapy boost (mean dose, 17 Gy) was given for 50 and 44 patients, respectively. Eight patients were subjected to neck node dissection, generally at the time of brachytherapy. At a median follow-up time of 95 months, 37 (39%) patients had no residual disease or locoregional recurrence, 34 (36%) patients had locoregional residual disease and 23 (25%) patients developed locoregional recurrence. The 5-year cause-specific survival for all patients was 45% (43 of 94). In multivariate analysis, N2-3 stage and histological grade 3 proved to be independent negative predictors of cause-specific survival (relative risk: 22 and 3.1, respectively). The overall number of patients with locoregional failure was 57. Salvage surgery was possible in 18 (32%) patients; more than half of the patients (31 of 57) with locoregional failure were not suitable for salvage surgery due to unresectable disease, poor health status or distant metastasis. Salvage surgery was successful in 10 (56%) patients, while 8 patients developed a second locoregional recurrence. For patients undergoing definitive RT, more effective follow-up and care is needed to increase the rate of salvage surgery.

KW - Base of tongue cancer

KW - Radiotherapy

KW - Salvage surgery

UR - http://www.scopus.com/inward/record.url?scp=57849121177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849121177&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 803

EP - 806

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -